Fabian Schuurmans

Fabian Schuurmans

Auto-generated profile, based on publicly available information

Fabian Schuurmans

Radboud University Medical Center 1 Radiotherapy and OncoImmunology Laboratory, Department of Radiation Oncology Nijmegen, the Netherlands

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2025 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
FSFabian Schuurmans
Fabian Schuurmans
AWAnja Wittner
Anja Wittner
RBRenske J.E. van Den Bijgaart
Renske J.E. van Den Bijgaart
STSiret Tahk
Siret Tahk
MBMatthia G.M. Boros
Matthia G.M. Boros
GAGosse J. Adema
Gosse J. Adema
Neuroblastoma is a childhood malignancy characterized by overexpression of disialoganglioside GD2. Treatment with anti-GD2 monoclonal antibodies (aGD2 mAb) has prolonged the survival of patients with neuroblastoma; however, long-term efficacy needs further improvement. Neuroblastoma tumor cells upregulate expression of the innate immune checkpoint and do not eat me signal CD47 to evade immune recognition and phagocytosis by signal regulatory protein alpha (SIRPα)-expressing myeloid cells. Targeting of CD47 remains challenging because ubiquitous CD47 expression on healthy cells causes on-target off-tumor related toxicities and functions as an antigen sink. To locally restrict CD47 blockade to the neuroblastoma tumor site, we successfully developed aGD2–SIRPα fusion mAbs for the murine and human setting. These fusion mAbs are equipped with a functional Fc-domain and the extracellular SIRPα domain 1 either fused to the N-terminus of the light chain or to the C-terminus of the heavy chain. Both aGD2–SIRPα fusion mAbs selectively bind neuroblastoma tumor cells and provide GD2-dependent SIRPα domain–mediated CD47 blockade. Furthermore, they potently induce innate immune effector mechanisms through the interaction of the mAbs Fc-domain with Fcγ receptors. Functional analysis of the fusion mAbs demonstrated enhanced phagocytosis and NK cell–mediated killing of neuroblastoma tumor cells compared with the conventional aGD2 mAb. In addition, these novel antibodies modulate the cytokine production by primary macrophages. The aGD2–SIRPα fusion mAbs outperformed aGD2 mAb across a broad range of CD47/GD2 coexpressing tumor cells. This research shows the successful development of aGD2–SIRPα fusion mAbs to provide targeted blockade of CD47 for the treatment of solid neuroblastoma tumors.

29 October 2026 in OncoImmunology
Verified
Journal Article
Open access
AVAnne H.C. Valk
Anne H.C. Valk
MBMatthia G.M. Boros
Matthia G.M. Boros
FSFabian Schuurmans
Fabian Schuurmans
GAGosse J. Adema
Gosse J. Adema
LCLenneke Cornelissen
Lenneke Cornelissen
Sialoglycans, carbohydrate structures terminated by negatively charged sialic acid residues, are expressed on the surface of virtually all mammalian cells. They are a crucial part of the glycocalyx...

21 April 2026 in Molecular Cancer Therapeutics
Verified
Journal Article
Closed access
FSFabian Schuurmans
Fabian Schuurmans
MBMatthia G.M. Boros
Matthia G.M. Boros
RBRenske J.E. van Den Bijgaart
Renske J.E. van Den Bijgaart
AWAnja Wittner
Anja Wittner
JMJanneke D.M. Molkenboer-Kuenen
Janneke D.M. Molkenboer-Kuenen
GAGosse J. Adema
Gosse J. Adema
Anti-GD2 monoclonal antibodies (aGD2 mAbs) are the standard immunotherapy for patients with high-risk neuroblastoma. This treatment has improved 5-year overall survival; however, long-term efficacy still requires improvement. The “don’t eat me” signal CD47 is upregulated on neuroblastoma tumor cells and inhibits aGD2 mAb effector mechanisms. Although GD2 is restrictively expressed on neuroblastoma tumor cells, CD47 expression is ubiquitous, resulting in an antigen sink and on-target off-tumor–related cytotoxicities. Recently, we developed two aGD2–SIRPα fusion mAbs for the murine and human settings. In vitro, these aGD2–SIRPα fusion mAbs restrict CD47 blockade toward GD2+ neuroblastoma tumor cells. In this study, we explored the tumor-targeting ability of aGD2–SIRPα fusion mAbs in a syngeneic 9464D-Luc-GFP and SK-N-AS xenograft neuroblastoma tumor model. Conventional aCD47 and aSIRPα mAbs encountered a dominant antigen sink in the 9464D-Luc-GFP model. Surprisingly, although aGD2 mAbs preferentially targeted tumors, murine aGD2–mSIRPα fusion mAbs accumulated in similar organs as aCD47 mAbs. Binding analysis of murine aGD2–mSIRPα and human aGD2–hSIRPα fusion mAbs to red blood cells (RBC) revealed strong binding of murine aGD2–mSIRPα to RBCs, whereas their human counterparts showed negligible binding. These data indicate species-specific CD47–SIRPα binding patterns. Utilizing a SK-N-AS xenograft model, we show effective tumor targeting of the human aGD2–hSIRPα fusion mAbs with hSIRPα in a C-terminal configuration. These data provide the first proof of principle for neuroblastoma tumor–targeted blockade of CD47 by aGD2–hSIRPα fusion mAbs in vivo and support the further development of aGD2–hSIRPα mAbs as attractive therapeutics to improve aGD2-based neuroblastoma immunotherapy.

17 June 2026
Verified
Other
Open access
FSFabian Schuurmans
Fabian Schuurmans
AWAnja Wittner
Anja Wittner
RBRenske J.E. van Den Bijgaart
Renske J.E. van Den Bijgaart
STSiret Tahk
Siret Tahk
MBMatthia G.M. Boros
Matthia G.M. Boros
GAGosse J. Adema
Gosse J. Adema
Supplementary Fig. 2 shows binding of the aCD33(-SIRPα fusion) mAbs to human and murine (NB) cell lines and binding of SIRPα fusion mAbs to SK-N-AS and the CD47 negative cell line HEPG2.

17 June 2026
Verified
Other
Open access
FSFabian Schuurmans
Fabian Schuurmans
AWAnja Wittner
Anja Wittner
RBRenske J.E. van Den Bijgaart
Renske J.E. van Den Bijgaart
STSiret Tahk
Siret Tahk
MBMatthia G.M. Boros
Matthia G.M. Boros
GAGosse J. Adema
Gosse J. Adema
Supplementary Fig. 5 shows the expression of CD16, CD47 and SIRPα on moMacs, the gating strategy used for the moMac phagocytosis assay, dose response curves of MCF-7 and SHEP-2 phagocytosis induced by aGD2(-SIRPα fusion) and aCD33-SIRPα fusion mAbs and the expression of TNFα in moMac cultures stimulated with or without LPS in presence of the various aGD2(-SIRPα fusion) maBs, aCD33(-SIRPα fusion) mAbs, CV1 or a combination of aGD2 and CV1.